The Far Side of Resistance to RAS Inhibitors

Michelangelo Marasco; Sandra Misale

doi:10.1158/2159-8290.CD-24-1153

The Far Side of Resistance to RAS Inhibitors

Cancer Discov. 2024 Nov 1;14(11):2018-2020. doi: 10.1158/2159-8290.CD-24-1153.

Authors

Michelangelo Marasco¹, Sandra Misale²

Affiliations

¹ Catholic University of the Sacred Heart and Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
² Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.

PMID: 39485257
DOI: 10.1158/2159-8290.CD-24-1153

Abstract

In this issue, four articles highlight the critical role of nongenetic mechanisms and cell plasticity in mediating resistance to different classes of RAS inhibitors in pancreatic ductal adenocarcinoma and non-small cell lung cancer. See related article by Benitz et al., p. 2162 See related article by Dilly et al., p. 2135 See related article by Araujo et al., p. 2183 See related article by Singhal et al., p. 2122.

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Pancreatic Ductal / drug therapy
Carcinoma, Pancreatic Ductal / pathology
Drug Resistance, Neoplasm*
Humans
Lung Neoplasms / drug therapy
Pancreatic Neoplasms / drug therapy
ras Proteins* / antagonists & inhibitors
ras Proteins* / metabolism

Substances

ras Proteins
Antineoplastic Agents